Modern treatment of patients at risk: still a HOPE for ACE inhibitors?

Bibliography

• Scholkens BA, Landgraf W. ACE inhibition and atherogenesis. Can J Physiol Pharmacol 2002;12:354-9
   Google Scholar
• Becker RC, Meade TW, Berger PB, The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133:776S-814S
   PubMed Web of Science ®Google Scholar
• Flather MD, Yusuf S, Kober L, Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-81
   PubMed Web of Science ®Google Scholar
• Danchin N, Cucherat M, Thuillez C, Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Arch Intern Med 2006;166:787-96
   PubMed Web of Science ®Google Scholar
• Ennezat PV, Vannesson C, Bouabdallaoui N, Imagine how many lives you save: angiotensin converting enzyme inhibition for vascular atherosclerosis in the present era of risk reduction. Expert Opin Pharmacother 2011;12(6):883-9
   Google Scholar
• Yusuf S, Sleight P, Pogue J, ; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53
   PubMed Web of Science ®Google Scholar
• MacMahon S, Sharpe N, Gamble G, Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of atherosclerosis with ramipril. J Am Coll Cardiol 2000;36:438-43
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moye LA, ; The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigattors. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91
   PubMed Web of Science ®Google Scholar
• Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8
   PubMed Web of Science ®Google Scholar
• Braunwald E, Domanski MJ, Fowler SE, Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68
   PubMed Web of Science ®Google Scholar
• Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. Br J Haematol 2009;146:27-30
   PubMed Web of Science ®Google Scholar
• Higgins J, Green SP. Cochrane handbook for systematic reviews of interventions. Wiley-Blackwell, Oxford; 2008
   Google Scholar
• Walter SD. Choice of effect measure for epidemiological data. J Clin Epidemiol 2000;53:931-9
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332
   PubMed Web of Science ®Google Scholar
• Szmitko PE, Wang CH, Weisel RD, Biomarkers of vascular disease linking inflammation to endothelial activation: part II. Circulation 2003;108:2041-8
   PubMed Web of Science ®Google Scholar
• Mancini GB, Henry GC, Macaya C, Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (trial on reversing endothelial dysfunction) Study. Circulation 1996;94:258-65
   PubMed Web of Science ®Google Scholar
• Pitt B, O'Neill B, Feldman R, The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87:1058-63
   PubMed Web of Science ®Google Scholar